MeiraGTx/$MGTX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About MeiraGTx

MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.

Ticker

$MGTX
Sector
Primary listing

Employees

386

MeiraGTx Metrics

BasicAdvanced
$612M
-
-$2.03
1.30
-

What the Analysts think about MeiraGTx

Analyst ratings (Buy, Hold, Sell) for MeiraGTx stock.

Bulls say / Bears say

The strategic partnership with Hologen AI brings $200 million upfront and commits up to $230 million more via a joint venture, fully financing AAV-GAD to commercialization, which significantly de-risks the Parkinson’s program and strengthens the company’s balance sheet (Nasdaq)
In May 2025, the FDA granted RMAT designation to AAV-GAD for Parkinson’s disease, citing positive Phase 2 sham-controlled results that showed significant UPDRS Part 3 improvements, setting the stage for expedited regulatory pathways and potential Priority Review (GlobeNewswire)
As of June 30, 2025, MeiraGTx had $34.4 million in cash and restricted cash, along with $2.3 million in J&J receivables and expected Hologen proceeds, providing funding runway through 2027 and coverage for the $75 million debt maturing in August 2026 (GlobeNewswire)
Cash and cash equivalents dropped 69% year-over-year from $103.7 million as of December 31, 2024 to $32.2 million on June 30, 2025, highlighting significant cash burn and heavy dependence on milestone payments to fund operations through 2027 (GlobeNewswire)
Patient enrollment in the high-dose cohorts of the Phase 2 AQUAx2 trial for AAV2-hAQP1 is ongoing, with completion not expected until Q4 2025, pushing pivotal data readout to late 2026 and delaying any BLA submission or potential revenue (GlobeNewswire)
MeiraGTx posted a net loss of $38.8 million in Q2 2025, demonstrating ongoing unprofitability and the risk of additional dilution if clinical development or regulatory milestones are delayed (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2025.

MeiraGTx Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

MeiraGTx Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MGTX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs